ACAD vs IDXX
ACADIA Pharmaceuticals Inc. vs Idexx Laboratories — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
71
Buy
VS
IDXX
Idexx Laboratories
69
Buy
| Metric | ACAD | IDXX |
|---|
| AI Score |
71
|
69
|
| Price |
$29.02
|
$546.21
|
| P/E Ratio |
12.55×
|
38.69×
|
| ROE |
31.9%
|
66.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
62.4%
|
| Debt / Equity |
0.06×
|
0.68×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.3
|
33.3
|
| Beta |
0.845
|
1.542
|
| Expected Upside |
+0.4%
|
+5.4%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus IDXX.
ACAD leads by 2 points.
ACAD scores 71/100 (Buy) versus IDXX at 69/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- Bollinger bandwidth of 26.0% signals elevated volatility — Risk
IDXX Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical